Objective: To determine the incidence of tuberculosis in person living with HIV infected by latent TB and under antiretroviral (ARV) therapy. Method: We studied prospectively for 36 months the occurrence of bacillifor...Objective: To determine the incidence of tuberculosis in person living with HIV infected by latent TB and under antiretroviral (ARV) therapy. Method: We studied prospectively for 36 months the occurrence of bacilliform pulmonary tuberculosis in patients infected with HIV, naive of BCG and receiving antiretroviral treatment. Each patient had an intradermal reaction (IDR) of 10 IU tuberculin Mérieux. The measurement of the nodule is made 72 hours later. During follow-up, patients were reviewed every six months for active tuberculosis. Results: A total of 212 out of 257 patients had an IDR greater than 5 mm, an ITL prevalence of 86.33%. Three patients were lost to follow-up during the study. The predominant female sex is 69.81%. The mean age was 42.8 ± 10.02 years. A previous history of tuberculosis was found in 14.15% of patients and 208 patients (98.11%) had HIV1. In 39.15% of patients, patients had a CD4 count lower than 350 cells/mm3 at baseline in the study. At the end of the three-year follow-up, among the 14 patients, 11 had failed ARV therapy and had developed TB, with an incidence of 2.20 cases per 100 patients. Conclusion: The incidence of active tuberculosis in LTBI was very high in HIV-positive patients with low CD4 count, hence the importance of reliable LTBI screening such as gamma interferon is better than patient follow-up.展开更多
Introduction: Tuberculosis (TB) remains a significant public health challenge, particularly in high-endemicity settings where latent TB infections (LTBI) contribute to ongoing transmission. Early identification and ma...Introduction: Tuberculosis (TB) remains a significant public health challenge, particularly in high-endemicity settings where latent TB infections (LTBI) contribute to ongoing transmission. Early identification and management of LTBI are crucial in limiting the spread of the disease. This study demonstrates the role of Interferon Gamma Release Assay (IGRA) as a screening tool for latent tuberculosis in high-burden region. Materials and Methods: This retrospective observational study assessed the detection of LTBI using the QuantiFERON-TB Gold Plus (QFT-Plus) test among 145 patients at the Department of Microbiology & Immunology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, from August 2023 to August 2024. The study included patients suspected of TB, those screened before immunosuppressive therapy, organ transplantation, or kidney dialysis. Participants were tested IGRA using QFT-Plus, which detects interferon-gamma (IFN-γ) released in response to Mycobacterium tuberculosis antigens. Results and Discussion: Among 145 patients tested for the QFT-Gold Plus test, 55.17% (n = 80) were positive for LTBI, with a substantial agreement between TB1 and TB2 responses (p Conclusion: The results highlight that QFT-Plus may be utilized as a useful diagnostic screening tool for latent TB in regions with a high disease burden, though challenges related to cost and infrastructure persist. With growing global efforts to eliminate tuberculosis, focused screening and treatment of LTBI in high-risk groups could play a vital role in reducing the progression of TB. The study underscores the importance of targeted screening for LTBI to reduce the progression to active TB, particularly in resource-limited settings.展开更多
Objective To identify potential serum biomarkers for distinguishing between latent tuberculosis infection（LTBI） and active tuberculosis（TB）. Methods A proteome microarray containing 4,262 antigens was used for scr...Objective To identify potential serum biomarkers for distinguishing between latent tuberculosis infection（LTBI） and active tuberculosis（TB）. Methods A proteome microarray containing 4,262 antigens was used for screening serum biomarkers of 40 serum samples from patients with LTBI and active TB at the systems level. The interaction network and functional classification of differentially expressed antigens were analyzed using STRING 10.0 and the TB database, respectively. Enzyme-linked immunosorbent assays（ELISA） were used to validate candidate antigens further using 279 samples. The diagnostic performances of candidate antigens were evaluated by receiver operating characteristic curve（ROC） analysis. Both antigen combination and logistic regression analysis were used to improve diagnostic ability. Results Microarray results showed that levels of 152 Mycobacterium tuberculosis（Mtb）-antigenspecific IgG were significantly higher in active TB patients than in LTBI patients（P 〈 0.05）, and these differentially expressed antigens showed stronger associations with each other and were involved in various biological processes. Eleven candidate antigens were further validated using ELISA and showed consistent results in microarray analysis. ROC analysis showed that antigens Rv2031 c, Rv1408, and Rv2421 c had higher areas under the curve（AUCs） of 0.8520, 0.8152, and 0.7970, respectively. In addition, both antigen combination and logistic regression analysis improved the diagnostic ability. Conclusion Several antigens have the potential to serve as serum biomarkers for discrimination between LTBI and active TB.展开更多
文摘Objective: To determine the incidence of tuberculosis in person living with HIV infected by latent TB and under antiretroviral (ARV) therapy. Method: We studied prospectively for 36 months the occurrence of bacilliform pulmonary tuberculosis in patients infected with HIV, naive of BCG and receiving antiretroviral treatment. Each patient had an intradermal reaction (IDR) of 10 IU tuberculin Mérieux. The measurement of the nodule is made 72 hours later. During follow-up, patients were reviewed every six months for active tuberculosis. Results: A total of 212 out of 257 patients had an IDR greater than 5 mm, an ITL prevalence of 86.33%. Three patients were lost to follow-up during the study. The predominant female sex is 69.81%. The mean age was 42.8 ± 10.02 years. A previous history of tuberculosis was found in 14.15% of patients and 208 patients (98.11%) had HIV1. In 39.15% of patients, patients had a CD4 count lower than 350 cells/mm3 at baseline in the study. At the end of the three-year follow-up, among the 14 patients, 11 had failed ARV therapy and had developed TB, with an incidence of 2.20 cases per 100 patients. Conclusion: The incidence of active tuberculosis in LTBI was very high in HIV-positive patients with low CD4 count, hence the importance of reliable LTBI screening such as gamma interferon is better than patient follow-up.
文摘Introduction: Tuberculosis (TB) remains a significant public health challenge, particularly in high-endemicity settings where latent TB infections (LTBI) contribute to ongoing transmission. Early identification and management of LTBI are crucial in limiting the spread of the disease. This study demonstrates the role of Interferon Gamma Release Assay (IGRA) as a screening tool for latent tuberculosis in high-burden region. Materials and Methods: This retrospective observational study assessed the detection of LTBI using the QuantiFERON-TB Gold Plus (QFT-Plus) test among 145 patients at the Department of Microbiology & Immunology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, from August 2023 to August 2024. The study included patients suspected of TB, those screened before immunosuppressive therapy, organ transplantation, or kidney dialysis. Participants were tested IGRA using QFT-Plus, which detects interferon-gamma (IFN-γ) released in response to Mycobacterium tuberculosis antigens. Results and Discussion: Among 145 patients tested for the QFT-Gold Plus test, 55.17% (n = 80) were positive for LTBI, with a substantial agreement between TB1 and TB2 responses (p Conclusion: The results highlight that QFT-Plus may be utilized as a useful diagnostic screening tool for latent TB in regions with a high disease burden, though challenges related to cost and infrastructure persist. With growing global efforts to eliminate tuberculosis, focused screening and treatment of LTBI in high-risk groups could play a vital role in reducing the progression of TB. The study underscores the importance of targeted screening for LTBI to reduce the progression to active TB, particularly in resource-limited settings.
基金supported by the Natural Science Foundation of China[No:81470091]Beijing Municipal Administration of Hospitals Ascent Plan[DFL20151501]
文摘Objective To identify potential serum biomarkers for distinguishing between latent tuberculosis infection（LTBI） and active tuberculosis（TB）. Methods A proteome microarray containing 4,262 antigens was used for screening serum biomarkers of 40 serum samples from patients with LTBI and active TB at the systems level. The interaction network and functional classification of differentially expressed antigens were analyzed using STRING 10.0 and the TB database, respectively. Enzyme-linked immunosorbent assays（ELISA） were used to validate candidate antigens further using 279 samples. The diagnostic performances of candidate antigens were evaluated by receiver operating characteristic curve（ROC） analysis. Both antigen combination and logistic regression analysis were used to improve diagnostic ability. Results Microarray results showed that levels of 152 Mycobacterium tuberculosis（Mtb）-antigenspecific IgG were significantly higher in active TB patients than in LTBI patients（P 〈 0.05）, and these differentially expressed antigens showed stronger associations with each other and were involved in various biological processes. Eleven candidate antigens were further validated using ELISA and showed consistent results in microarray analysis. ROC analysis showed that antigens Rv2031 c, Rv1408, and Rv2421 c had higher areas under the curve（AUCs） of 0.8520, 0.8152, and 0.7970, respectively. In addition, both antigen combination and logistic regression analysis improved the diagnostic ability. Conclusion Several antigens have the potential to serve as serum biomarkers for discrimination between LTBI and active TB.
